North America Non-Steroidal Anti-Inflammatory Drugs Market to Reach $17.27 Billion by 2033 | Leading companies - Bayer AG, Haleon group of companies, Kenvue, Teva Pharmaceutical Industries Ltd

Leander, Texas and Tokyo, Japan - Dec.10.2025
As per DataM intelligence research report" The North America non-steroidal anti-inflammatory drugs market size reached US$ 8.34 billion in 2024 and is expected to reach US$ 17.27 billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033." Chronic pain prevalence and OTC self-care trends continue to strengthen the NSAIDs market.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/north-america-non-steroidal-anti-inflammatory-drugs-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, Pfizer launched a new topical NSAID gel with enhanced skin permeation The product delivers higher drug concentrations to the joint while minimizing systemic absorption It offers a safer option for osteoarthritis patients with gastrointestinal risks

✅ In October 2025, The FDA approved a combination drug containing ibuprofen and acetaminophen for post-op pain The fixed-dose combination reduces the need for opioid prescriptions after dental surgery It supports the ongoing federal effort to combat the opioid crisis

✅ In September 2025, A generic manufacturer released a liquid-filled naproxen capsule for faster relief The formulation dissolves quicker than traditional tablets for rapid onset It competes in the highly competitive U.S. OTC pain relief market

✅ In August 2025, Researchers at Yale published a study on the cardiovascular safety of COX-2 inhibitors The real-world data confirmed the safety of celecoxib compared to non-selective NSAIDs It reassures U.S. prescribers about using targeted NSAIDs for chronic pain

Japan: Recent Industry Developments

✅ In December 2025, Hisamitsu Pharmaceutical released a new ultra-thin NSAID patch "Salonpas Pro" The patch is designed to be invisible under clothing and flexible for joint movement It fits the lifestyle of active Japanese office workers suffering from stiff shoulders

✅ In November 2025, Kowa Company launched a "Loxoprofen" tape with a cooling sensation The product combines the analgesic effect of loxoprofen with menthol for immediate relief It caters to the Japanese consumer preference for cooling transdermal products

✅ In October 2025, Taisho Pharmaceutical introduced a smaller, easier-to-swallow ibuprofen tablet The design targets female consumers who frequently use painkillers for menstrual pain It addresses the "pill burden" concern in the Japanese market

✅ In September 2025, The MHLW issued a safety alert regarding the renal effects of long-term NSAID use in the elderly The alert encourages doctors to monitor kidney function in older patients It promotes safer prescribing practices in Japan's aging society

North America Non Steroidal Anti Inflammatory Drugs Market: Drivers
The North American NSAID market continues to expand as the prevalence of chronic pain, arthritis, and musculoskeletal disorders rises. NSAIDs provide pain relief, anti-inflammatory effects, and fever reduction, with both prescription and over-the-counter formulations catering to diverse patient needs. Technological innovations in drug delivery, including topical gels, extended-release tablets, and combination therapies, enhance efficacy and safety. Market growth is supported by geriatric population expansion and lifestyle-related inflammatory conditions.

Pharmaceutical companies invest in developing safer NSAID alternatives to reduce gastrointestinal and cardiovascular side effects. Regulatory oversight ensures compliance, proper labeling, and post-marketing surveillance, maintaining patient trust. Increased consumer preference for self-managed pain solutions, e-pharmacies, and home care further supports market penetration. The North American NSAID market remains a cornerstone in pain management therapies, combining accessibility with ongoing innovation.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/north-america-non-steroidal-anti-inflammatory-drugs-market?Prasad

North America Non Steroidal Anti Inflammatory Drugs Market: Major Players
Bayer AG, Haleon group of companies, Kenvue, Teva Pharmaceutical Industries Ltd., Viatris Inc., Pfizer Inc., Abbott, Sun Pharmaceutical Industries Ltd., among others.

Segment Covered in the North America Non Steroidal Anti Inflammatory Drugs Market:
By Therapy
The NSAIDs market in North America is categorized into Over-the-Counter (OTC) NSAIDs and Prescription NSAIDs, covering a broad class of analgesics used for pain, inflammation, and fever management. OTC options such as ibuprofen, naproxen, and aspirin dominate in volume due to accessibility and widespread use in mild-to-moderate conditions. Prescription-strength therapies, including COX-2 inhibitors and higher-dose formulations, serve patients requiring targeted and extended relief. The mix of OTC and prescription therapies continues to evolve as safety profiles, regulatory updates, and consumer preferences shape usage patterns across the region.

By Indication
NSAIDs are widely used across major indications including Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain, Chronic Pain, Dysmenorrhea, and Others. Osteoarthritis and chronic pain represent the largest demand due to high prevalence among aging populations in the U.S. and Canada. Rheumatoid arthritis and inflammatory joint disorders continue to rely on NSAIDs for symptomatic relief despite biologics expansion. Acute pain segments-such as surgical pain, sports injuries, and traumatic pain also contribute significantly. The broad therapeutic range ensures continuous adoption across primary care, orthopedic, and rheumatology settings.

By Mode of Prescription
The market is segmented into OTC (Over-the-Counter) and Prescription-Based NSAIDs. OTC NSAIDs dominate due to consumer self-management trends and availability in retail pharmacies, supermarkets, and online channels. Prescription NSAIDs, including specialized COX-2 inhibitors and high-dose formulations, maintain strong demand for managing severe and chronic inflammatory conditions. Regulatory oversight, physician preference, and patient safety considerations (such as GI and cardiovascular risks) influence prescribing patterns, driving a balanced yet growing consumption across both distribution modes in North America.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=north-america-non-steroidal-anti-inflammatory-drugs-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.